News & Views
Deal Opens Pathway for Analyte Development
Mar 18 2021
Cancer therapies and diagnostics developer Avacta Group plc has signed an agreement with Biokit, a Werfen Company, to incorporate its Affimer reagents into an in-vitro diagnostic (IVD) product for detection of a key analyte of interest.
Under the licence, Biokit has the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners, an in-vitro diagnostic (IVD) immunoassay for this analyte. Avacta will receive royalties on future sales of any products brought to market following completion of product development and regulatory approvals.
Details of the agreement were not disclosed.
Dr Marta Palicio, Innovation Director of Biokit commented: "Biokit is very pleased to have reached this agreement with Avacta. The agreement will increase the competitiveness of our customised assay offering for our partners. Avacta’s technology also enables us to innovate our assays with new reagents like Affimer reagents, an alternative to antibodies. We can now move onto the next stage of development, incorporation of this technology into new products. We hope this is the first of many assays containing Affimer reagents which will be developed by Avacta.”
Digital Edition
Lab Asia April 2022
April 2022
In This Edition Chromatography - Achiral Supercritical Fluid Chromatography (SFC) for the Purification of Pharmaceuticals - Equivalent GC systems performance for regulatory method compliance...
View all digital editions
Events
May 29 2022 Virtual event
May 31 2022 Frankfurt, Germany
Jun 05 2022 Minneapolis, MN, USA
Jun 08 2022 Rotterdam, Netherlands
ChemBio Finland 2022 - NEW DATES
Jun 08 2022 Helsinki, Finland